Kirsten Miller-Jaster, Apryl Susi, Cade M. Nylund, K. Lieuw, Gregory H Gorman
{"title":"羟基脲用于镰状细胞性贫血患者未充分利用，即使在全民卫生保健系统","authors":"Kirsten Miller-Jaster, Apryl Susi, Cade M. Nylund, K. Lieuw, Gregory H Gorman","doi":"10.1542/PEDS.147.3_MEETINGABSTRACT.1044","DOIUrl":null,"url":null,"abstract":"Background: Sickle cell anemia (SCA) is a common hematologic disease in the US which results in severe morbidity and mortality affecting the African American population. Hydroxyurea is a safe and efficacious drug that decreases ischemic events and end-organ damage. Hydroxyurea was found in a randomized placebo controlled trial (BABY HUG) to be beneficial to children and was strongly recommended for pediatric use in 2014. There is concern that this therapy, now considered standard of care, remains underutilized. Objective: We aim to describe …","PeriodicalId":143776,"journal":{"name":"Section on Uniformed Services Program","volume":"85 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2021-02-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Hydroxyurea Use for Sickle Cell Anemia Patients is Underutilized Even Within a Universal Health Care System\",\"authors\":\"Kirsten Miller-Jaster, Apryl Susi, Cade M. Nylund, K. Lieuw, Gregory H Gorman\",\"doi\":\"10.1542/PEDS.147.3_MEETINGABSTRACT.1044\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Background: Sickle cell anemia (SCA) is a common hematologic disease in the US which results in severe morbidity and mortality affecting the African American population. Hydroxyurea is a safe and efficacious drug that decreases ischemic events and end-organ damage. Hydroxyurea was found in a randomized placebo controlled trial (BABY HUG) to be beneficial to children and was strongly recommended for pediatric use in 2014. There is concern that this therapy, now considered standard of care, remains underutilized. Objective: We aim to describe …\",\"PeriodicalId\":143776,\"journal\":{\"name\":\"Section on Uniformed Services Program\",\"volume\":\"85 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2021-02-24\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Section on Uniformed Services Program\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1542/PEDS.147.3_MEETINGABSTRACT.1044\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Section on Uniformed Services Program","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1542/PEDS.147.3_MEETINGABSTRACT.1044","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Hydroxyurea Use for Sickle Cell Anemia Patients is Underutilized Even Within a Universal Health Care System
Background: Sickle cell anemia (SCA) is a common hematologic disease in the US which results in severe morbidity and mortality affecting the African American population. Hydroxyurea is a safe and efficacious drug that decreases ischemic events and end-organ damage. Hydroxyurea was found in a randomized placebo controlled trial (BABY HUG) to be beneficial to children and was strongly recommended for pediatric use in 2014. There is concern that this therapy, now considered standard of care, remains underutilized. Objective: We aim to describe …
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
